The global cancer immunotherapy market was valued at $85,603.50 million in 2020, and is projected to reach $309,667.65 million by 2030, registering a CAGR of 14.1% from 2021 to 2030.
Cancer immunotherapy is a method of cancer treatment that helps in boosting immune system in fighting cancer. This therapy is more advantageous than the traditional approach, as it delivers long-term protection against cancer. Cancer immunotherapy is known to cause minimal side effects, and helps in treating various cancer types. Immunotherapy guides immune system toward cancer-specific targets, then activates immune system to mobilize the target, and produces response to eradicate cancer targeted cells. Cancer immunotherapy is extensively used in different types of cancers such as breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, head & neck cancer, and others.
There are many factors that affect the market growth. These include increase in incidence of cancer worldwide, rise in healthcare expenditure, surge in geriatric population, and increase in healthcare expenditure in the cancer treatment therapies. According to the World Health Organization in 2020, cancer was a leading cause of death across the globe. Furthermore, the statistics suggested that the deaths caused due to cancer were about 10 million deaths in 2020. This steep rise in the incidences of cancer is anticipated to propel the growth of the industry in the coming years. Surge in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period.
However, factor such as stringent regulations related to cancer immunotherapy is anticipated to inhibit the growth of the cancer immunotherapy market. Government has been showing greater supervision over the use of immunotherapy and is also taking care of the clinical trials going on. These regulations have made it difficult for various medium and small scale companies to enter the cancer immunotherapy market and is hence anticipated to hinder the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented on the basis of technology type, application, End User, and region. By technology type, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By End User, it is divided into hospitals, cancer research centers, and clinics. By region, it is studied across North America, Europe, Asia Pacific, and LAMEA
Key players operating in the global cancer immunotherapy market include Amgen, Inc., Astrazeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, and Novartis AG.
Cancer immunotherapy is a method of cancer treatment that helps in boosting immune system in fighting cancer. This therapy is more advantageous than the traditional approach, as it delivers long-term protection against cancer. Cancer immunotherapy is known to cause minimal side effects, and helps in treating various cancer types. Immunotherapy guides immune system toward cancer-specific targets, then activates immune system to mobilize the target, and produces response to eradicate cancer targeted cells. Cancer immunotherapy is extensively used in different types of cancers such as breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, head & neck cancer, and others.
There are many factors that affect the market growth. These include increase in incidence of cancer worldwide, rise in healthcare expenditure, surge in geriatric population, and increase in healthcare expenditure in the cancer treatment therapies. According to the World Health Organization in 2020, cancer was a leading cause of death across the globe. Furthermore, the statistics suggested that the deaths caused due to cancer were about 10 million deaths in 2020. This steep rise in the incidences of cancer is anticipated to propel the growth of the industry in the coming years. Surge in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period.
However, factor such as stringent regulations related to cancer immunotherapy is anticipated to inhibit the growth of the cancer immunotherapy market. Government has been showing greater supervision over the use of immunotherapy and is also taking care of the clinical trials going on. These regulations have made it difficult for various medium and small scale companies to enter the cancer immunotherapy market and is hence anticipated to hinder the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented on the basis of technology type, application, End User, and region. By technology type, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By End User, it is divided into hospitals, cancer research centers, and clinics. By region, it is studied across North America, Europe, Asia Pacific, and LAMEA
Key players operating in the global cancer immunotherapy market include Amgen, Inc., Astrazeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, and Novartis AG.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global cancer immunotherapy market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global cancer immunotherapy market growth
KEY MARKET SEGMENTS
By Technology Type
- Monoclonal Antibodies
- Cytokines & Immunomodulators
- Others
By Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
By End User
- Hospitals
- Cancer Research Centers
- Clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Amgen, Inc.
- Astrazeneca, PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lily And Company
- F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
- Pfizer, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Merck KGAA
- Novartis AG
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of cancer diseases
3.5.1.2. Rise in geriatric population
3.5.1.3. Growth in awareness among consumers regarding cancer immunotherapy
3.5.1.4. Increase in expenditure for the healthcare sector
3.5.2. Restraints
3.5.2.1. Risk of allergic reaction and limitations of the cancer immunotherapy treatment
3.5.2.2. Stringent government regulations
3.5.3. Opportunity
3.5.3.1. Increasing research and development in cancer immunotherapy
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the cancer immunotherapy market
CHAPTER 4: CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Monoclonal antibodies
4.2.1. Market size and forecast, by region
4.2.2. Market analysis, by country
4.3. Cytokines & Immunomodulators
4.3.1. Market size and forecast, by region
4.3.2. Market analysis, by country
4.4. Others
4.4.1. Market size and forecast, by region
4.4.2. Market analysis, by country
CHAPTER 5: CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Breast Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Colorectal Cancer
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Melanoma
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Prostate Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Head & Neck Cancer
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Others
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
CHAPTER 6: CANCER IMMUNOTHERAPY MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Cancer Research Centers
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Clinics
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: CANCER IMMUNOTHERAPY MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. North America market size and forecast, by technologies type
7.2.2. North America market size and forecast, by application
7.2.3. North America market size and forecast, by end user
7.2.4. North America market size and forecast, by country
7.2.5. U. S.
7.2.5.1. U. S. market size and forecast, by technologies type
7.2.5.2. U. S. market size and forecast, by application
7.2.5.3. U. S. market size and forecast, by end user
7.2.6. Canada
7.2.6.1. Canada market size and forecast, by technologies type
7.2.6.2. Canada market size and forecast, by application
7.2.6.3. Canada market size and forecast, by end user
7.2.7. Mexico
7.2.7.1. Mexico market size and forecast, by technologies type
7.2.7.2. Mexico market size and forecast, by application
7.2.7.3. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Europe market size and forecast, by technologies type
7.3.2. Europe market size and forecast, by application
7.3.3. Europe market size and forecast, by end user
7.3.4. Europe market size and forecast, by country
7.3.5. Germany
7.3.5.1. Germany market size and forecast, by technologies type
7.3.5.2. Germany market size and forecast, by application
7.3.5.3. Germany market size and forecast, by end user
7.3.6. France
7.3.6.1. France market size and forecast, by technologies type
7.3.6.2. France market size and forecast, by application
7.3.6.3. France market size and forecast, by end user
7.3.7. UK
7.3.7.1. UK market size and forecast, by technologies type
7.3.7.2. UK market size and forecast, by application
7.3.7.3. UK market size and forecast, by end user
7.3.8. Italy
7.3.8.1. Italy market size and forecast, by technologies type
7.3.8.2. Italy market size and forecast, by application
7.3.8.3. Italy market size and forecast, by end user
7.3.9. Spain
7.3.9.1. Spain market size and forecast, by technologies type
7.3.9.2. Spain market size and forecast, by application
7.3.9.3. Spain market size and forecast, by end user
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe market size and forecast, by technologies type
7.3.10.2. Rest of Europe market size and forecast, by application
7.3.10.3. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Asia-Pacific market size and forecast, by technologies type
7.4.2. Asia-Pacific market size and forecast, by application
7.4.3. Asia-Pacific market size and forecast, by end user
7.4.4. Asia-Pacific market size and forecast, by country
7.4.5. Japan
7.4.5.1. Japan market size and forecast, by technologies type
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by end user
7.4.6. China
7.4.6.1. China market size and forecast, by technologies type
7.4.6.2. China market size and forecast, by application
7.4.6.3. China market size and forecast, by end user
7.4.7. India
7.4.7.1. India market size and forecast, by technologies type
7.4.7.2. India market size and forecast, by application
7.4.7.3. India market size and forecast, by end user
7.4.8. Rest of Asia-Pacific
7.4.8.1. Rest of Asia-Pacific market size and forecast, by technologies type
7.4.8.2. Rest of Asia-Pacific market size and forecast, by application
7.4.8.3. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. LAMEA market size and forecast, by technologies type
7.5.2. LAMEA market size and forecast, by application
7.5.3. LAMEA market size and forecast, by end user
7.5.4. LAMEA market size and forecast, by country
7.5.5. Latin America
7.5.5.1. Latin America market size and forecast, by technologies type
7.5.5.2. Latin America market size and forecast, by application
7.5.5.3. Latin America market size and forecast, by end user
7.5.6. Middle East
7.5.6.1. Middle East market size and forecast, by technologies type
7.5.6.2. Middle East market size and forecast, by application
7.5.6.3. Middle East market size and forecast, by end user
7.5.7. Africa
7.5.7.1. Africa market size and forecast, by technologies type
7.5.7.2. Africa market size and forecast, by application
7.5.7.3. Africa market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. AMGEN, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ASTRAZENECA, PLC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. BAYER AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. BRISTOL-MYERS SQUIBB COMPANY
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. ELI LILY AND COMPANY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. JOHNSON & JOHNSON (Janssen Global Services, LLC)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. MERCK KGAA
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. NOVARTIS AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. PFIZER INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developmentsLIST OF TABLES
TABLE 01. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE, 2020-2030 ($MILLION)
TABLE 02. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY REGION, 2020-2030 ($MILLION)
TABLE 03. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY REGION, 2020-2030 ($MILLION)
TABLE 04. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 05. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 06. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEALTHCARE, BY REGION, 2020-2030 ($MILLION)
TABLE 07. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 08. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 09. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY REGION, 2020-2030 ($MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2020-2030 ($MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 17. CANCER IMMUNOTHERAPY MARKET, BY REGION, 2020-2030, ($MILLION)
TABLE 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020-2030, ($MILLION)
TABLE 21. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 22. U.S. CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 23. U.S. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 24. U.S. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 25. CANADA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 26. CANADA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 27. CANADA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 28. MEXICO CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 29. MEXICO CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 30. MEXICO CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 31. EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 32. EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 33. EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020-2030, ($MILLION)
TABLE 34. EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 35. GERMANY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 36. GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 37. GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 38. FRANCE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 39. FRANCE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 40. FRANCE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 41. UK CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 42. UK CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 43. UK CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 44. ITALY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 45. ITALY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 46. ITALY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 47. SPAIN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 48. SPAIN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 49. SPAIN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 50. REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 51. REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 52. REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 53. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 54. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 55. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020-2030, ($MILLION)
TABLE 56. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 57. JAPAN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 58. JAPAN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 59. JAPAN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 60. CHINA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 61. CHINA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 62. CHINA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 63. INDIA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 64. INDIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 65. INDIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 69. LAMEA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 70. LAMEA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 71. LAMEA CANCER IMMUNOTHERAPY MARKET, BY END USE, 2020-2030, ($MILLION)
TABLE 72. LAMEA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 73. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 74. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 75. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 76. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 77. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 78. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 79. AFRICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 2020-2030, ($MILLION)
TABLE 80. AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 81. AFRICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 82. MEDTRONIC: COMPANY SNAPSHOT
TABLE 83. AMGEN: OPERATING SEGMENTS
TABLE 84. AMGEN: PRODUCT PORTFOLIO
TABLE 85. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 86. ASTRAZENECA INC.: OPERATING SEGMENTS
TABLE 87. ASTRAZENECA INC.: PRODUCT PORTFOLIO
TABLE 88. BAYER : COMPANY SNAPSHOT
TABLE 89. BAYER : OPERATING SEGMENT
TABLE 90. BAYER : PRODUCT PORTFOLIO
TABLE 91. BMS: COMPANY SNAPSHOT
TABLE 92. BMS: PRODUCT PORTFOLIO
TABLE 93. ELI LILLY: COMPANY SNAPSHOT
TABLE 94. LILLY: OPERATING SEGMENTS
TABLE 95. ELI LILLY: PRODUCT PORTFOLIO
TABLE 96. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. ROCHE: COMPANY SNAPSHOT
TABLE 98. ROCHE : OPERATING SEGMENTS
TABLE 99. ROCHE : PRODUCT PORTFOLIO
TABLE 100. ROCHE : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. J&J: COMPANY SNAPSHOT
TABLE 102. J&J: OPERATING BUSINESS SEGMENTS
TABLE 103. J&J: PRODUCT PORTFOLIO
TABLE 104. J&J : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. MERCK: COMPANY SNAPSHOT
TABLE 106. MERCK: OPERATING SEGMENTS
TABLE 107. MERCK: PRODUCT PORTFOLIO
TABLE 108. NOVARTIS: COMPANY SNAPSHOT
TABLE 109. NOVARTIS: OPERATING SEGMENT
TABLE 110. NOVARTIS : PRODUCT PORTFOLIO
TABLE 111. PFIZER: COMPANY SNAPSHOT
TABLE 112. PFIZER: OPERATING SEGMENT
TABLE 113. PFIZER: PRODUCT PORTFOLIOLIST OF FIGURES
FIGURE 01. GLOBAL CANCER IMMUNOTHERAPY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07. HIGH BARGAINING POWER OF BUYERS
FIGURE 08. HIGH THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR LUNG CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25. COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26. AMGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29. ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32. BAYER : NET SALES, 2018-2020 ($MILLION)
FIGURE 33. BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34. BAYER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35. BMS: NET SALES, 2018-2020 ($MILLION)
FIGURE 36. BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37. ELI LILLY: NET SALES, 2018-2020 ($MILLION)
FIGURE 38. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39. ELI LILLY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 41. ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42. ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43. J&J: NET SALES, 2018-2020 ($MILLION)
FIGURE 44. J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45. J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 46. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 47. MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48. MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 50. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51. NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 52. PFIZER: NET SALES, 2018-2020 ($MILLION)
FIGURE 53. PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
Companies Mentioned
- Bayer AG
- Bristol-Myers Squibb Company
- Amgen Inc.
- Astrazeneca
- PLC
- Eli Lily And Company
- F. Hoffmann-La Roche Ltd. (Genentech Inc.)
- Pfizer Inc.
- Johnson & Johnson (Janssen Global Services LLC)
- Merck KGAA
- Novartis AG.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 207 |
| Published | July 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 85603.5 million |
| Forecasted Market Value ( USD | $ 309667.65 million |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
